Human immune deficiency virus (HIV) infection and the hypothalamic pituitary adrenal axis
Tóm tắt
The hypothalamic pituitary adrenal (HPA) axis is the most common of the endocrine lines/axis’ to be affected by HIV infection. There are multiple factors that contribute to this HPA axis dysregulation. Direct invasion of the various organs in the axis can be either by opportunistic infections or infiltrative diseases. The soluble factors or cytokines released during viral infection and the chronic inflammatory state that follows, also contribute to these alterations. The actions of these cytokines released by the immune response can both activate the HPA axis and cause a glucocorticoid resistant state. Further, many of the anti-retroviral and other medications used to treat HIV infection can contribute to HPA axis dysfunction. While the diagnosis and treatment of endocrine dysfunction is the same as in any other patient, management pathways may be quite different. While some may be adaptive responses, life threatening adrenal insufficiency can also be present. It is important the latter be picked up expeditiously and treated promptly to avoid mortality.
Tài liệu tham khảo
UNAIDS/WHO.: AIDS epidemic update. Edited by 2009, p.
Grinspoon SK, Bilezikian JP. HIV disease and the endocrine system. N Engl J Med. 1992;327:1360–5.
Eledrisi MS, Verghese AC. Adrenal insufficiency in HIV infection: a review and recommendations. Am J Med Sci. 2001;321:137–44.
Shashidhar PK, Shashikala GV. Low dose adrenocorticotropic hormone test and adrenal insufficiency in critically ill acquired immunodeficiency syndrome patients. Indian J Endocrinol Metab. 2012;16:389–94.
Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med. 1995;332:1351–62.
Chrousos GP, Gold PW. The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis. JAMA. 1992;267:1244–52.
Rivier C, Brownstein M, Spiess J, Rivier J, Vale W. In vivo corticotropin-releasing factor-induced secretion of adrenocorticotropin, beta-endorphin, and corticosterone. Endocrinology. 1982;110:272–8.
Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science. 1981;213:1394–7.
Conaglen JV, Donald RA, Espiner EA, Livesey JH, Nicholls MG. The effect of ovine corticotropin-releasing factor on catecholamine, vasopressin, and aldosterone secretion in normal man. J Clin Endocrinol Metab. 1984;58:463–6.
Dittmar KD, Demady DR, Stancato LF, Krishna P, Pratt WB. Folding of the glucocorticoid receptor by the heat shock protein (hsp) 90-based chaperone machinery. The role of p23 is to stabilize receptor.hsp90 heterocomplexes formed by hsp90.p60.hsp70. J Biol Chem. 1997;272:21213–20.
Dittmar KD, Pratt WB. Folding of the glucocorticoid receptor by the reconstituted Hsp90-based chaperone machinery. The initial hsp90.p60.hsp70-dependent step is sufficient for creating the steroid binding conformation. J Biol Chem. 1997;272:13047–54.
Pratt WB, Toft DO. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev. 1997;18:306–60.
Cheung J, Smith DF. Molecular chaperone interactions with steroid receptors: an update. Mol Endocrinol. 2000;14:939–46.
Davies TH, Ning YM, Sanchez ER. A new first step in activation of steroid receptors: hormone-induced switching of FKBP51 and FKBP52 immunophilins. J Biol Chem. 2002;277:4597–600.
Wochnik GM, Ruegg J, Abel GA, Schmidt U, Holsboer F, Rein T. FK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the glucocorticoid receptor in mammalian cells. J Biol Chem. 2005;280:4609–16.
Sakai DD, Helms S, Carlstedt-Duke J, Gustafsson JA, Rottman FM, Yamamoto KR. Hormone-mediated repression: a negative glucocorticoid response element from the bovine prolactin gene. Genes Dev. 1988;2:1144–54.
Drouin J, Trifiro MA, Plante RK, Nemer M, Eriksson P, Wrange O. Glucocorticoid receptor binding to a specific DNA sequence is required for hormone-dependent repression of pro-opiomelanocortin gene transcription. Mol Cell Biol. 1989;9:5305–14.
Ray A, Prefontaine KE. Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci U S A. 1994;91:752–6.
Stocklin E, Wissler M, Gouilleux F, Groner B. Functional interactions between Stat5 and the glucocorticoid receptor. Nature. 1996;383:726–8.
Croxtall JD, Choudhury Q, Flower RJ. Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism. Br J Pharmacol. 2000;130:289–98.
Gross KL, Cidlowski JA. Tissue-specific glucocorticoid action: a family affair. Trends Endocrinol Metab. 2008;19:331–9.
Guarda LA, Luna MA, Smith Jr JL, Mansell PW, Gyorkey F, Roca AN. Acquired immune deficiency syndrome: postmortem findings. Am J Clin Pathol. 1984;81:549–57.
Tapper ML, Rotterdam HZ, Lerner CW, Al’Khafaji K, Seitzman PA. Adrenal necrosis in the acquired immunodeficiency syndrome. Ann Intern Med. 1984;100:239–41.
Guenthner EE, Rabinowe SL, Van Niel A, Naftilan A, Dluhy RG. Primary Addison’s disease in a patient with the acquired immunodeficiency syndrome. Ann Intern Med. 1984;100:847–8.
Greene LW, Cole W, Greene JB, Levy B, Louie E, Raphael B, et al. Adrenal insufficiency as a complication of the acquired immunodeficiency syndrome. Ann Intern Med. 1984;101:497–8.
Staras SA, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ. Seroprevalence of cytomegalovirus infection in the United States, 1988–1994. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2006;43:1143–51.
Hoshino Y, Nagata Y, Gatanaga H, Hosono O, Morimoto C, Tachikawa N, et al. Cytomegalovirus (CMV) retinitis and CMV antigenemia as a clue to impaired adrenocortical function in patients with AIDS. AIDS. 1997;11:1719–24.
Glasgow BJ, Steinsapir KD, Anders K, Layfield LJ. Adrenal pathology in the acquired immune deficiency syndrome. Am J Clin Pathol. 1985;84:594–7.
Arabi Y, Fairfax MR, Szuba MJ, Crane L, Schuman P. Adrenal insufficiency, recurrent bacteremia, and disseminated abscesses caused by Nocardia asteroides in a patient with acquired immunodeficiency syndrome. Diagn Microbiol Infect Dis. 1996;24:47–51.
Baker R, Rook GA, Zumla A. Adrenal function and the hypothalamo-pituitary adrenal axis in immunodeficiency virus-associated tuberculosis. Int J Tuberc Lung Dis: Off J Int Union Tuberc Lung Dis. 1997;1:289–90.
Baraia-Etxaburu Artetxe J, Astigarraga Aguirre B, Elorza Olabegova R, Teira Cobo R, Yoldi Arrieta A, Cisterna Cancer R, et al. [Primary adrenal failure and AIDS: report of 11 cases and review of the literature]. Rev Clin Esp. 1998;198:74–9.
Radin DR, Esplin JA, Levine AM, Ralls PW. AIDS-related non-Hodgkin’s lymphoma: abdominal CT findings in 112 patients. AJR Am J Roentgenol. 1993;160:1133–9.
Tappero JW, Conant MA, Wolfe SF, Berger TG. Kaposi’s sarcoma. Epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy. J Am Acad Dermatol. 1993;28:371–95.
Welch K, Finkbeiner W, Alpers CE, Blumenfeld W, Davis RL, Smuckler EA, et al. Autopsy findings in the acquired immune deficiency syndrome. JAMA. 1984;252:1152–9.
Niedt GW, Schinella RA. Acquired immunodeficiency syndrome. Clinicopathologic study of 56 autopsies. Arch Pathol Lab Med. 1985;109:727–34.
Zapanti E, Terzidis K, Chrousos G. Dysfunction of the hypothalamic-pituitary-adrenal axis in HIV infection and disease. Hormones (Athens). 2008;7:205–16.
Chrousos GP. The stress response and immune function: clinical implications. The 1999 Novera H. Spector Lecture. Ann N Y Acad Sci. 2000;917:38–67.
Petrovsky N. Towards a unified model of neuroendocrine-immune interaction. Immunol Cell Biol. 2001;79:350–7.
Imura H, Fukata J, Mori T. Cytokines and endocrine function: an interaction between the immune and neuroendocrine systems. Clin Endocrinol (Oxf). 1991;35:107–15.
Kageyama K, Tamasawa N, Suda T. Signal transduction in the hypothalamic corticotropin-releasing factor system and its clinical implications. Stress. 2011;14:357–67.
Shearer GM, Clerici M, Sarin A, Berzofsky JA, Henkart PA. Cytokines in immune regulation/pathogenesis in HIV infection. CIBA Found Symp. 1995;195:142–7. discussion 147–153.
Clerici M. New research hypotheses in the immunopathogenesis of human immunodeficiency virus infection. Q J Nucl Med. 1995;39:163–8.
Clerici M, Fusi ML, Ruzzante S, Piconi S, Biasin M, Arienti D, et al. Type 1 and type 2 cytokines in HIV infection – a possible role in apoptosis and disease progression. Ann Med. 1997;29:185–8.
Norbiato G, Bevilacqua M, Vago T, Baldi G, Chebat E, Bertora P, et al. Cortisol resistance in acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74:608–13.
Norbiato G, Bevilacqua M, Vago T, Clerici M. Glucocorticoids and interferon-alpha in the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1996;81:2601–6.
Norbiato G, Bevilacqua M, Vago T, Taddei A, Clerici. Glucocorticoids and the immune function in the human immunodeficiency virus infection: a study in hypercortisolemic and cortisol-resistant patients. J Clin Endocrinol Metab. 1997;82:3260–3.
Norbiato G, Bevilacqua M, Vago T, Clerici M. Glucocorticoid resistance and the immune function in the immunodeficiency syndrome. Ann N Y Acad Sci. 1998;840:835–47.
Mirani M, Elenkov I, Volpi S, Hiroi N, Chrousos GP, Kino T. HIV-1 protein Vpr suppresses IL-12 production from human monocytes by enhancing glucocorticoid action: potential implications of Vpr coactivator activity for the innate and cellular immunity deficits observed in HIV-1 infection. J Immunol. 2002;169:6361–8.
Kino T, Chrousos GP. Human immunodeficiency virus type-1 accessory protein Vpr: a causative agent of the AIDS-related insulin resistance/lipodystrophy syndrome? Ann N Y Acad Sci. 2004;1024:153–67.
Andersen JL, Planelles V. The role of Vpr in HIV-1 pathogenesis. Curr HIV Res. 2005;3:43–51.
Sawaya BE, Khalili K, Gordon J, Taube R, Amini S. Cooperative interaction between HIV-1 regulatory proteins Tat and Vpr modulates transcription of the viral genome. J Biol Chem. 2000;275:35209–14.
Kino T, Gragerov A, Kopp JB, Stauber RH, Pavlakis GN, Chrousos GP. The HIV-1 virion-associated protein vpr is a coactivator of the human glucocorticoid receptor. J Exp Med. 1999;189:51–62.
Wahl LM, Corcoran ML, Pyle SW, Arthur LO, Harel-Bellan A, Farrar WL. Human immunodeficiency virus glycoprotein (gp120) induction of monocyte arachidonic acid metabolites and interleukin 1. Proc Natl Acad Sci U S A. 1989;86:621–5.
Raber J, Toggas SM, Lee S, Bloom FE, Epstein CJ, Mucke L. Central nervous system expression of HIV-1 Gp120 activates the hypothalamic-pituitary-adrenal axis: evidence for involvement of NMDA receptors and nitric oxide synthase. Virology. 1996;226:362–73.
Pozzoli G, Tringali G, Dello Russo C, Vairano M, Preziosi P, Navarra P. HIV-1 Gp120 protein modulates corticotropin releasing factor synthesis and release via the stimulation of its mRNA from the rat hypothalamus in vitro: involvement of inducible nitric oxide synthase. J Neuroimmunol. 2001;118:268–76.
Raffi F, Brisseau JM, Planchon B, Remi JP, Barrier JH, Grolleau JY. Endocrine function in 98 HIV-infected patients: a prospective study. AIDS. 1991;5:729–33.
Christeff N, Gharakhanian S, Thobie N, Rozenbaum W, Nunez EA. Evidence for changes in adrenal and testicular steroids during HIV infection. J Acquir Immune Defic Syndr. 1992;5:841–6.
Verges B, Chavanet P, Desgres J, Vaillant G, Waldner A, Brun JM, et al. Adrenal function in HIV infected patients. Acta Endocrinol (Copenh). 1989;121:633–7.
Membreno L, Irony I, Dere W, Klein R, Biglieri EG, Cobb E. Adrenocortical function in acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1987;65:482–7.
Dobs AS, Dempsey MA, Ladenson PW, Polk BF. Endocrine disorders in men infected with human immunodeficiency virus. Am J Med. 1988;84:611–6.
Biglino A, Limone P, Forno B, Pollono A, Cariti G, Molinatti GM, et al. Altered adrenocorticotropin and cortisol response to corticotropin-releasing hormone in HIV-1 infection. Eur J Endocrinol. 1995;133:173–9.
Hilton CW, Harrington PT, Prasad C, Svec F. Adrenal insufficiency in the acquired immunodeficiency syndrome. South Med J. 1988;81:1493–5.
Thaler LM, Blevins Jr LS. The low dose (1-microg) adrenocorticotropin stimulation test in the evaluation of patients with suspected central adrenal insufficiency. J Clin Endocrinol Metab. 1998;83:2726–9.
Wolff FH, Nhuch C, Cadore LP, Glitz CL, Lhullier F, Furlanetto TW. Low-dose adrenocorticotropin test in patients with the acquired immunodeficiency syndrome. Braz J Infect Dis. 2001;5:53–9.
Foisy MM, Yakiwchuk EM, Chiu I, Singh AE. Adrenal suppression and Cushing’s syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature. HIV Med. 2008;9:389–96.
Dort K, Padia S, Wispelwey B, Moore CC. Adrenal suppression due to an interaction between ritonavir and injected triamcinolone: a case report. AIDS Res Ther. 2009;6:10.
Mann M, Koller E, Murgo A, Malozowski S, Bacsanyi J, Leinung M. Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature. Arch Intern Med. 1997;157:1651–6.
Subramanian S, Goker H, Kanji A, Sweeney H. Clinical adrenal insufficiency in patients receiving megestrol therapy. Arch Intern Med. 1997;157:1008–11.